Bioxyne Limited

BXN

Bioxyne Ltd. engages in the research, development, market and distribution of health products. The company is headquartered in Sydney, New South Wales. The company went IPO on 2000-12-14. The firm is focused on health and wellness products, psychotropic and investigational medicines. The firm operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries Japan, Australia, the United Kingdom, and Czechia. The firm direct sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.

Dart Mining NL

DTM

Dart Mining NL engages in the exploration, evaluation, and development of orogenic gold, prophyry gold, and lithium opportunities in North East Victoria. The firm is focused on mineral exploration activities in lithium-cesium-tantal (Li-Cs-Ta) pegmatites, orogenic gold, and base metal porphyry targets. Its mineral exploration activities also include silver, copper, molybdenum, zinc, tungsten, tin and tantalum. Its Dorchap Lithium Project includes lithium prospectivity of pegmatite dykes in the Dorchap Range. Its Granite Flat (copper and gold) Project is located within its northeast exploration region between Mitta Mitta and Glen Wills. Its Triumph Gold Project is located approximately 520km by road north of Brisbane, Queensland. The firm's tenements include Mountain View Project, Fairleys Project, Mitta, Unicorn Project, Rushworth, Mt Creek, Eskdale, Buckland, Dart Goldfields, Cudgewa and Deddick.

Polynovo Limited

PNV

Polynovo Ltd. engages in the development of medical devices, utilizing the patented polymer technology NovoSorb. The company is headquartered in Melbourne, Victoria and currently employs 282 full-time employees. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.

Recce Pharmaceuticals Ltd

RCE

Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.

Emyria Limited

EMD

Emyria Ltd. is a healthcare technology and services company. The company is headquartered in Leederville, Western Australia. The company went IPO on 2020-02-12. The firm is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises medication-assisted treatment programs and biopharmaceuticals, specifically methylenedioxy-methylamphetamine (MDMA) analogues and Ultra-Pure cannabidiol (CBD) capsules. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.